[en] BM-573 (N-terbutyl-N'-[2-(4'-methylphenylamino)-5-nitro-benzenesulfonyl]urea), a torsemide derivative, is a novel non-carboxylic dual TXA2 synthase inhibitor and receptor antagonist. The pharmacological profile of the drug is characterized by a higher affinity for the thromboxane receptor than that of SQ-29548, one of the most powerful antagonists described to date, by a complete prevention of human platelet aggregation induced by arachidonic acid at a lower dose than either torsemide or sulotroban, and by a significantly prolonged closure time measured by the platelet function analyser (PFA-100). Moreover, at the concentrations of 1 and 10 microM, BM-573 completely prevented production of TXB2 by human platelets activated by 0.6 mM of arachidonic acid. BM-573 prevents rat fundus contraction induced by U-46619 but not by prostacyclin or other prostaglandins. Despite possessing a chemical structure very similar to that of a diuretic torsemide, BM-573 has no diuretic activity. BM-573 does not prolong bleeding time and, unlike some of the other sulfonylureas, has no effect on blood glucose levels. In vivo, BM-573 appears to have antiplatelet and antithrombotic activities since it reduced thrombus weight and prolonged the time to abdominal aorta occlusion induced by ferric chloride. BM-573 also relaxed rat aorta and guinea pig trachea precontracted with U-46619. In pigs, BM-573 completely antagonized pulmonary hypertensive effects of U-46619 and reduced the early phase of pulmonary hypertension in models of endotoxic shock and pulmonary embolism. Finally, BM-573 protected pigs from myocardial infarction induced by coronary thrombosis. These results suggest that BM-573 should be viewed as a promising therapeutic agent in the treatment of pulmonary hypertension and syndromes associated with platelet activation.
Disciplines :
Pharmacy, pharmacology & toxicology
Author, co-author :
Ghuysen, Alexandre ; Université de Liège - ULiège > Département des sciences de la santé publique > Réanimation - Urgence extrahospitalière
Dogné, Jean-Michel
Chiap, Patrice ; Université de Liège - ULiège > Département de pharmacie > Département de pharmacie
Rolin, Stephanie
Masereel, Bernard
Lambermont, Bernard ; Centre Hospitalier Universitaire de Liège - CHU > Frais communs médecine
Kolh, Philippe ; Centre Hospitalier Universitaire de Liège - CHU
Bhagwat SS, Hamann PR, Still WC, Bunting S, Fitzpatrick FA. Synthesis and structure of the platelet aggregation factor thromboxane A2. Nature 1985;315:511-513.
Brezinski ME, Yanagisawa A, Lefer AM. Cardioprotective actions of specific thromboxane receptor antagonist in acute myocardial ischemia. J Cardiovasc Pharmacol 1987;9:65-71.
Cocks TM, King SJ, Angus JA. Glibenclamide is a competitive antagonist of the thromboxane A2 receptor in dog coronary artery in vitro. Br J Pharmacol 1990;100:375-378.
Coleman RA, Humphrey PP, Kennedy I, Levy GP, Lumley P. Comparison of the actions of U-46619, a prostaglandin H2-analogue, with those of prostaglandin H2 and thromboxane A2 on some isolated smooth muscle preparations. Br J Pharmacol 1981;73:773-778.
Collins BJ, Blum MG, Parker RE, et al. Thromboxane mediates pulmonary hypertension and lung inflammation during hyperacute lung rejection. J Appl Physiol 2001;90:2257-2268.
D'Orio V, Lambermont B, Detry O, et al. Pulmonary impedance and right ventricular-vascular coupling in endotoxin shock. Cardiovasc Res 1998;38:375-382.
De Clerck F, Beetens J, Van de WA, Vercammen E, Janssen PA. R 68 070: Thromboxane A2 synthetase inhibition and thromboxane A 2/prostaglandin endoperoxide receptor blockade combined in one molecule. II. Pharmacological effects in vivo and ex vivo. Thromb Haemost 1989;61:43-49.
Dogne JM, de Leval, X, Kolh P, et al. Pharmacological evaluation of the novel thromboxane modulator BM-567 (I/II). Effects of BM-567 on platelet function. Prostaglandins Leukot Essent Fatty Acids 2003;68: 49-54.
Dogne JM, de Leval, X, Neven P, et al. Effects of a novel non-carboxylic thromboxane A2 receptor antagonist (BM-531) derived from torasemide on platelet function. Prostaglandins Leukot Essent Fatty Acids 2000;62:311-317.
Dogne JM, Hanson J, de Leval, X, et al. Pharmacological characterization of N-tert-butyl-N′-[2-(4′-methyl-phenylamino)-5- nitrobenzenesulfonyl]urea (BM-573), a novel thromboxane A2 receptor antagonist and thromboxane synthase inhibitor in a rat model of arterial thrombosis and its effects on bleeding time. J Pharmacol Exp Ther 2004;309:498-505.
Dogne JM, Wouters J, Rolin S, et al. Design, synthesis and biological evaluation of a sulfonylcyanoguanidine as thromboxane A2 receptor antagonist and thromboxane synthase inhibitor. J Pharm Pharmacol 2001; 53:669-680.
Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105:1650-1655.
Ellis EF, Oelz O, Roberts LJ, et al. Coronary arterial smooth muscle contraction by a substance released from platelets: Evidence that it is thromboxane A2. Science 1976;193:1135-1137.
Fiddler GI, Lumley P. Preliminary clinical studies with thromboxane synthase inhibitors and thromboxane receptor blockers. A review. Circulation 1990;81:169-178.
Fishbein MC, Meerbaum S, Rit J, et al. Early phase acute myocardial infarct size quantification: Validation of the triphenyl tetrazolium chloride tissue enzyme staining technique. Am Heart J 1981;101:593-600.
Fitzgerald DJ, Roy L, Catella F, Fitzgerald GA. Platelet activation in unstable coronary disease. N Engl J Med 1986;315:983-989.
Ghuysen A, Lambermont B, Dogné JM, et al. Effect of BM-573 [N-terbutyl-N′-[2-(4′-methylphenyl-amino)-5-nitro-benzenesulfonyl] urea], a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, in a porcine model of acute pulmonary embolism. J Pharmacol Exp Ther 2004;310:964-972.
Granstrom E, Diczfalusy U, Hamberg M, Hansson G, Malmsten C, Samuelsson B. Thromboxane A2: Biosynthesis and effects on platelets. Adv Prostaglandin Thromboxane Leukot Res 1982;10:15-58.
Hamberg M, Svensson J, Samuelsson B. Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975;72:2994-2998.
Hamberg M, Svensson J, Wakabayashi T, Samuelsson B. Isolation and structure of two prostaglandin endoperoxides that cause platelet aggregation. Proc Natl Acad Sci USA 1974;71:345-349.
Hamm CW, Lorenz RL, Bleifeld W, Kupper W, Wober W, Weber PC. Biochemical evidence of platelet activation in patients with persistent unstable angina. J Am Coll Cardiol 1987;10:998-1006.
Heylen L, De Clerck F, Somers Y, Leysen JE. Thromboxane A2 per prostaglandin endoperoxide (TXA2/PG-END) receptor binding properties in human platelets of ridogrel, a combined TXA2 synthase inhibitor - TXA2 per PG-END receptor antagonist. Blood Coagul Fibrinolysis 1991;2:617-621.
Hirsh PD, Firth BG, Campbell WB, Dehmer GJ, Willerson JT, Hillis LD. Effects of provocation on transcardiac thromboxane in patients with coronary artery disease. Am J Cardiol 1983;51:727-733.
Hirsh PD, Hillis LD, Campbell WB, Firth BG, Willerson JT. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med 1981;304:685-691.
Hock CE, Brezinski ME, Lefer AM. Anti-ischemic actions of a new thromboxane receptor antagonist, SQ-29,548, in acute myocardial ischemia. Eur J Pharmacol 1986;122:213-219.
Hoshino M, Sim J, Shimizu K, Nakayama H, Koya A. Effect of AA-2414, a thromboxane A2 receptor antagonist, on airway inflammation in subjects with asthma. J Allergy Clin Immunol 1999;103:1054-1061.
Imamoto T, Terashita Z, Tanabe M, Nishikawa K, Hirata M. Protective effect of a novel thromboxane synthetase inhibitor, CV-4151, on myocardial damage due to coronary occlusion and reperfusion in the hearts of anesthetized dogs. J Cardiovasc Pharmacol 1986;8:832-839.
Kundu SK, Heilmann EJ, Sio R, Garcia C, Davidson RM, Ostgaard RA. Description of an in vitro platelet function analyzer - PFA-100. Semin Thromb Hemost 1995;21(Suppl 2):106-112.
Lambermont B, Ghuysen A, Dogne JM, et al. Effects of BM-573, a novel thromboxane A2 inhibitor, on pulmonary hemodynamics in endotoxic shock. Arch Physiol Biochem 2003;111:224-231.
Lambermont B, Ghuysen A, Kolh P, et al. Effects of endotoxic shock on right ventricular systolic function and mechanical efficiency. Cardiovasc Res 2003;59:412-418.
Lambermont B, Kolh P, Dogne JM, et al. Effects of U-46619 on pulmonary hemodynamics before and after administration of BM-573, a novel thromboxane A2 inhibitor. Arch Physiol Biochem 2003;111:217-223.
Lambermont B, Kolh P, Ghuysen A, et al. Effect of a novel thromboxane A2 inhibitor on right ventricular-arterial coupling in endotoxic shock. Shock 2004;21:45-51.
Lebrun P, Arkhammar P, Antoine MH, Nguyen QA, Hansen JB, Pirotte B. A potent diazoxide analogue activating ATP-sensitive K+ channels and inhibiting insulin release. Diabetologia 2000;43:723-732.
Ma H, Hara A, Xiao CY, et al. Increased bleeding tendency and decreased susceptibility to thromboembolism in mice lacking the prostaglandin E receptor subtype EP(3). Circulation 2001;104:1176-1180.
Masereel B, Damas J, Fontaine J, et al. Thromboxane A2 receptor antagonism in man and rat by a sulphonylcyanoguanidine (BM-144) and a sulphonylurea (BM-500). J Pharm Pharmacol 1999;51:695-701.
Needleman P, Wyche A, Raz A. Platelet and blood vessel arachidonate metabolism and interactions. J Clin Invest 1979;63:345-349.
Nijkamp FP, Moncada S, White HL, Vane JR. Diversion of prostaglandin endoperoxide metabolism by selective inhibition of thromboxane A2 biosynthesis in lung, spleen or platelets. Eur J Pharmacol 1977;44: 179-186.
Ogletree ML, Brigham KL. Effects of cyclooxygenase inhibitors on pulmonary vascular responses to endotoxin in unanesthetized sheep. Prostaglandins Leukot Med 1982;8:489-502.
Pawlowski NA, Kaplan G, Hamill AL, Cohn ZA, Scott WA. Arachidonic acid metabolism by human monocytes. Studies with platelet-depleted cultures. J Exp Med 1983;158:393-412.
Rolin S, Dogne JM, Michaux C, Delarge J, Masereel B. Activity of a novel dual thromboxane A2 receptor antagonist and thromboxane synthase inhibitor (BM-573) on platelet function and isolated smooth muscles. Prostaglandins Leukot Essent Fatty Acids 2001;65:67-72.
Rolin S, Petein M, Tchana-Sato V, et al. BM-573, a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, prevents pig myocardial infarction induced by coronary thrombosis. J Pharmacol Exp Ther 2003;306:59-65.
Saldeen TG, Saldeen P, Nichols WW, Lawson DL, Nicolini FA, Mehta JL. Increased production of thromboxane A2 by coronary arteries after thrombolysis. Am Heart J 1993;125:277-284.
Smulders YM. Pathophysiology and treatment of haemodynamic instability in acute pulmonary embolism: The pivotal role of pulmonary vasoconstriction. Cardiovasc Res 2000;48:23-33.
Stanke F, Cracowski JL, Chavanon O, et al. Glibenclamide inhibits thromboxane A2-induced contraction in human internal mammary artery and saphenous vein. Eur J Pharmacol 1998;341:65-71.
Stein PD and Henry JW. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Chest 1995;108:978-981.
Svensson J, Hamberg M, Samuelsson B. On the formation and effects of thromboxane A2 in human platelets. Acta Physiol Scand 1976;98:285-294.
Tanaka T, Ito S, Higashino R, et al. A new thromboxane receptor antagonist, Z-335, ameliorates experimental thrombosis without prolonging the rat tail bleeding time. Thromb Res 1998;91:229-235.
The Ridrogel Versus Aspirin Patency Trial. Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A 2 per prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspirin Patency Trial (RAPT). Circulation 1994;89:588-595.
Uchida T, Kido H, Yamanaga K, Okita M, Watanabe M. A novel loop diuretic, torasemide, inhibits thromboxane A2-induced contraction in the isolated canine coronary artery. Prostaglandins Leukot Essent Fatty Acids 1992;45:121-124.
Watts IS, Wharton KA, White BP, Lumley P. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets. Br J Pharmacol 1991;102:497-505.
Wise WC, Cook JA, and Halushka PV. Implications for thromboxane A 2 in the pathogenesis of endotoxic shock. Adv Shock Res 1981;6:83-91.
